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25 Objectives: Kallikrein-related peptidases (KLKs) are a subgroup of 15 secreted chymotrypsin- and 
26 trypsin-like serine proteases that have been reported to possess novel functions in innate immunity and 
27 inflammation. Since the potential role of KLKs in immunity has not been studied in detail at the protein 
28 level, we examined the expression pattern of 12 members of the KLK family in immune-related tissues. 
29 Design & Methods： Protein expression in tissue extracts was evaluated using immunoassays 
30 (ELISA). Immunohistochemistry (IHC) was performed on representative sections of tonsil and lymph 
31 nodes to determine the cellular localization of the KLK family members. 
32 Results: ELISA profiling of KLK3-KLK15 (except KLK12) revealed higher protein levels in the 
33 tonsil, compared to the lymph nodes and spleen. Relatively high protein levels in the tonsil were 
34 observed for KLK7, KLK9, KLK10 and KLK13. Expression of these KLKs was significantly lower 
35 in lymph nodes and spleen. IHC analysis in tonsil unveiled that KLK9 and KLK10 were differentially 
36 expressed in lymphoid cells. KLK9 was strongly expressed in the germinal center of lymphoid follicles 
37 where activated B-cells reside, whereas KLK10 was expressed in the follicular dendritic cells (FDCs) 
38 that are vital for maintaining the cycle of B cell maturation. 
39 Conclusion: Overall, our study revealed the possible implications of KLK expression and regulation 
40 in the immune cells of lymphoid tissues. 
41 Keywords






47 Proteolysis plays a central role in immune functions, such as immune cell activation, 
48 inflammatory cell extravasation, cytokine production and complement activation [1, 2]. A wide variety 
49 of serine proteases have been discovered in immune cells, such as cytotoxic lymphocytes and 
50 neutrophils [1]. Serine, cysteine, and metalloproteases have also been associated with several immune-
51 related tissues [3]. Proteases can also regulate other proteolytic enzymes [4], with the deregulation of 
52 protease networks being linked to several pathologies involving the immune response [5, 6]. 
53 Human tissue kallikrein-related peptidases (KLKs) constitute a subgroup of 15 secreted 
54 trypsin- or chymotrypsin-like serine proteases [7]. Their aberrant regulation has been linked to diseases 
55 such as neurodegeneration, inflammatory skin conditions and cancer [8]. There is also emerging 
56 evidence of KLKs participating in the initiation of systemic inflammatory responses and immune-
57 modulated disorders via proteolytic cascades [9, 10]. KLK6, for instance, is strongly upregulated in 
58 activated immune cells in the central nervous system and is expressed by inflammatory cells in multiple 
59 sclerosis [11]. KLK7 can  promote inflammation by cleaving pro-IL1b and producing active IL1b[12]. 
60 Moreover, pro-inflammatory roles of KLK5 and KLK6 in Netherton syndrome have been reported [13, 
61 14]. KLK1 expression/localization in inmmune tissues/cells has also been reviewed [15]. KLK activity 
62 has also been associated with certain autoimmune diseases [16, 17]. 
63 The ability of proteolytic enzymes such as KLKs to cleave extracellular matrix (ECM) proteins 
64 has been shown to influence the migration of immune cells through tissues and vascular walls [1, 18]. 
65 KLKs also assist in innate immunity through proteolytic cleavage, which generates antimicrobial 
66 peptides from protein precursors [10, 19, 20]. KLK5, KLK6, and KLK14 cleave and activate the 
67 proteinase-activated receptor-2 (PAR2) with implications for inflammation [21]. Given the putative 
68 function of KLKs in the immune response, a better understanding of their role in immune cells may 
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69 help unravel the underlying processes behind immunological disorders and lead to new therapeutic 
70 targets [1]. 
71 We sought to investigate the expression patterns of the KLK family in immune-related 
72 lymphoid tissues, with a focus on tonsil, lymph nodes and spleen. To date, research regarding KLKs 
73 in lymphoid tissues have mostly focused on the mRNA level, where preliminary studies revealed the 
74 presence of KLK mRNA in lymph nodes and Peyer's patches [22], as well as in neutrophils [23]. In 
75 the present study, we mined public databases for KLK mRNA expression in lymphoid tissues before 
76 utilizing ELISA immunoassays to measure protein concentrations of 12 KLK family members in these 
77 tissues. Finally, we used immunohistochemical (IHC) (Table 1) to visualize the expression patterns of 
78 13 KLK family members at the cellular level to provide a comprehensive picture. 
79
80 2. Materials and Methods
81 2.1 In silico analysis of KLKs mRNA expression in immune-related tissues 
82 The pattern of KLK mRNA expression in normal bone marrow and primary and secondary lymphoid 
83 tissue was determined by analyzing data from "The Human Protein Atlas" 
84 (https://www.proteinatlas.org/). KLK1-KLK15 expression in appendix, spleen, bone marrow, lymph 
85 node, and tonsil was indicated as number of TPM (Human Protein atlas) (http://www.proteinatlas.org/) 
86 (Table 2). For comparative analysis, the high, moderate and lower expression levels were arbitrarily 
87 defined as: 0-0.2 (very low), 0.3-0.5 (low), 0.6-0.9 (moderate), 1.0-10 (high), >10 (very high).
88
89 2.2 Tissue extract preparation
90 The Research Ethics Board (REB) of Mount Sinai Hospital, Toronto, Canada, approved this study. 
91 The following human tissues were retrieved from adult individuals at autopsy: tonsil, lymph nodes, 
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92 and spleen. Tissue extracts were processed from two patient samples and examined for 12 KLKs. 
93 Tissue cytosolic extracts were prepared from snap-frozen tissues as previously described [24]. Briefly, 
94 fresh frozen human tissues were pulverized to a fine powder in 0.2 g/ml of extraction buffer. Cell 
95 suspensions were incubated on ice for 30 min, mixing every 5 min, and centrifuged at 15,000 g for 30 
96 min at 4 °C. The clear supernatants (cytosolic extracts) were collected and stored at -80 °C until use.
97
98 2.3 ELISA assays
99 Sandwich-type ELISAs for 12 KLKs were performed using in-house or commercial mouse
100  monoclonal antibodies (mAbs) for capturing and detection as follows: 1) biotinylated mAbs 
101 (monoclonal-monoclonal ELISA configuration), or 2) rabbit polyclonal antibodies followed by 
102 alkaline phosphatase goat anti-rabbit IgG (monoclonal-polyclonal ELISA configuration) (see refs in 
103 Table 1; [25]). Detailed description of each antibody and protocol that was used is presented in ref. 
104 section of Table 1. In brief, microtiter plates were coated with an anti-KLK monoclonal antibody 
105 (KLK3-KLK15 at concentration of 500 ng/100uL, diluted in 50 mM Tris buffer (pH 7.8) and incubated 
106 overnight. The following day, plates were washed three times, and each of the tissue extracts, diluted 
107 in Buffer A (60 g/L BSA, 25 ml/L normal mouse serum, 100 ml/L normal goat serum, 10 g/L bovine 
108 IgG, 0.005% (v/v) Tween-20 in 50 mM Tris, pH 7.8), was added and incubated at RT (2h). 
109 Subsequently, plates were washed three times and 100 µl of each secondary biotinylated monoclonal 
110 antibody, diluted appropriately in Buffer A (KLK3 (1/2000); KLK5 (1/2000); KLK6 (1/2000); KLK7 
111 (1/1000); KLK8 (1/1000); KLK9 (1/1000); KLK10 (1/500); KLK11 (1/1000) and KLK13 (1/500)) 
112 was added. The rabbit polyclonal antibodies were also prepared by dilutions in Buffer A (KLK4 
113 (1/2000); KLK14 (1/2000); KLK15 (1/3000)), and incubated for 1h at room temperature (RT). Plates 
114 were washed three times. Either alkaline phosphatase-conjugated streptavidin (SA-ALP), prepared in 
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115 6% BSA (mono-monoclonal combination), or alkaline phosphatase-conjugated goat anti-rabbit IgG 
116 (mono-polyclonal combination), prepared in Buffer B (60 g/L BSA, 25 ml/L normal mouse serum, 
117 100 ml/L normal goat serum, 10 g/L bovine IgG, 0.005% (v/v) Tween-20 in 50 mM Tris, pH 7.8, 0.5 
118 M KCl), was added to each well, and incubated for 15 or 30 min, respectively. Then, the plates were 
119 washed six times and 100 ul of diflunisal phosphate (DFP) solution, prepared in substrate buffer (0.1 
120 M NaCl, 1 mM MgCl2 in 0.1 M Tris, pH 9.1), was added to the plate and incubated for 10 minutes at 
121 RT with gentle shaking. Subsequently, the developing solution (1 M Tris, 0.4 M NaOH, 2 mM TbCl3 
122 and 3 mM EDTA)(100 μl per well) was added and mixed for 1 min. Time-resolved fluorescence was 
123 measured with the Wallac EnVision 2103 Multilabel Reader (Perkin Elmer), as previously described 
124 [24].
125
126 2.4 Immunohistochemistry 
127 Representative samples from three normal tonsils and two normal lymph nodes were studied by IHC. 
128 Negative controls in the tonsil and lymph node were also used, where the tissue was processed and 
129 stainined according the same procedure described below with the only difference being no primary 
130 antibodies were added. Formalin-fixed, paraffin-embedded tissues were cut to 4-um sections and 
131 stained using in-house mouse monoclonal and rabbit polyclonal antibodies, as previously described 
132 (Table 1). The specificity of each antibody was evaluated prior using Western blot (Table 1). The 
133 staining procedures involved paraffin removal with three changes of xylene (3 min each), followed by 
134 one change of xylene:/ethanol (1:1) (3 min each), and further rehydration through decreasing 
135 concentrations of ethanol (100%-95%-70%-50%) for 3 min each. Finally, the slides were rehydrated 
136 with water for 5 min. Antigen retrieval was carried out by incubating the slides in buffer (citrate; pH 
137 6.0, 0.05 % Tween-20) in a microwave for 5 min. Following one wash with water (10 min) and two 
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138 washes with phosphate-buffered saline (PBS) (5 min each), the endogenous peroxidase activity was 
139 blocked with BLOXALL™ Blocking Solution (SP-6000, Vector Laboratories, Inc., CA, USA) for 10 
140 min. After one wash with PBS (5 min), slides were blocked with buffer (3% BSA+2% normal goat 
141 serum) for 20 min, and each KLK primary antibody, diluted in 2% BSA, was incubated overnight at 4 
142 oC (Table 1). After three washes with PBS (5 min each), the sections were then incubated with 
143 ImmPRESS peroxidase reagent anti-mouse IgG and anti-rabbit IgG (for mouse monoclonal and rabbit 
144 polyclonal primary antibodies, respectively) (ImmPress HRP reagent kit, Vector Laboratories, 
145 Burlingame, CA, USA) for 1h at RT. After three washes with PBS (5 min per), immunostaining was 
146 visualized using DAB solution (DAB kit SK-4100) for 2-10 min (brown color). Following wash with 
147 water and three washes with PBS (2 min per), sections were counterstained with hematoxylin for 1 
148 min, washed with water (10 min), dehydrated through increasing alcohol concentrations, cleared in 
149 xylene, and finally mounted. The staining pattern, distribution of the immunostaining in each tissue, 
150 and intensity of the staining were evaluated in detail using a LEICA DMLB microscope.
151
152 3. Results
153 3.1 KLK mRNA expression in lymphoid tissues 
154 KLK mRNA levels, as number of transcripts per million (TPM), in normal bone marrow and 
155 primary and secondary lymphoid tissues were investigated by mining The Human Protein Atlas 
156 database (https://www.proteinatlas.org/) (Table 2). Strongest expression was observed in the tonsil, 
157 with higher KLK mRNA levels for the majority of the KLK family members (Table 2). Specifically, 
158 KLK6, KLK7, KLK10, KLK11, KLK12 and KLK13 demonstrated relatively very high KLK mRNA 
159 levels (>10 TPM) in tonsil. KLK1, KLK4, KLK8, and KLK9 showed moderate to high levels (within 
160 0.6-10 TPM), while KLK2, KLK3, KLK5, KLK14, and KLK15 had undetectable to low levels in tonsil 
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161 (within 0-0.5 TPM). High to very high mRNA levels of KLK2, KLK6 and KLK7 were seen in spleen 
162 (within 1-10 TPM). KLK1, KLK2, KLK3, and KLK4 were elevated in appendix (within 1-10 TPM). 
163 In bone marrow, moderate to high mRNA levels were detected for KLK1, KLK2, KLK4, and KLK10 
164 (within 0.6-10TPM), while the other KLKs had undetectable to low levels. In lymph nodes, 
165 undetectable to low mRNA levels were seen for all KLK members, except KLK1, KLK2, KLK3, 
166 KLK4, and KLK14 (Table 2).
167
168 3.2 Protein levels of the KLK family in immune-related tissues 
169 We assessed the protein concentration of KLKs in tissue extracts from the tonsil, lymph node, and 
170 spleen for the 12 family members where reliable ELISA immunoassays were available. In general, KLK 
171 levels were higher in the tonsil than the rest of the tissues analyzed, where KLK7, KLK9, KLK10, and 
172 KLK13 were detected at relatively high levels (ranging from 3.30 to 9.28 ng/mL) (Table 3). Moderate 
173 protein levels of KLK6 and KLK11 was observed in tonsil (2.05 and 1.81 ng/ml respectively). KLK13 
174 also showed the highest protein level in the spleen (1.51±0.06 ng/mL), compared to other KLKs analyzed 
175 (Table 3). 
176
177 3.3 IHC analysis of KLKs in normal tonsil and lymph nodes
178 IHC analysis was performed for 13 KLK family members in normal tonsil and lymph node 
179 tissues from three and two individuals, respectively. In tonsil, only KLK9, KLK10 and KLK15 showed 
180 positive staining (Figure 1A-C), with  KLK9 and KLK10 displaying different staining patterns in 
181 tonsil (Figure 2). KLK9 expression was strong in the activated B-cells of the germinal center (GC) in 
182 the lymphoid follicles (Figure 2A and B), whereas KLK10 expression was localized to the follicular 
183 dendritic cells (FDCs) (Figure 2C and D). In addition, KLK15 demonstrated some staining in the 
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184 interdigitating cells in and subjacent to the tonsillar epithelium (Figure 2E). All other KLKs showed 
185 equivocal or undetectable staining patterns (Supplementary Figure 1).
186 In lymph node, positive protein staining was identified for KLK5 (Figure 3A) and KLK10 
187 (Figure 3B). KLK5 showed the strongest staining in the peripheral cells surrounding the follicles 
188 (Figure 3A). KLK10 showed the strongest staining in the FDCs of the lymph node tissue (Figure 3B), 
189 although expression in lymph node was overall weaker than in tonsil. All other KLKs were 
190 undetectable (Supplementary Figure 2).
191
192 4. Discussion
193 Aberrant KLK activity and regulation have been implicated in inflammatory diseases [11, 26], 
194 where these enzymes regulate inflammation via PARs [27] and play a role in the innate immunity via 
195 the complement cascade through interaction with C3 [28]. KLKs also digest ECM components to 
196 promote infiltration of macrophages and T-cells [10]. We sought to explore the (co)expression of 
197 KLKs in lymphoid organs to better understanding their contribution to immunity.  
198 We first mined the Human Protein Atlas to study KLKs expression in immune-related tissues, 
199 finding that KLK mRNA levels were generally higher in the tonsil (Table 2). We next performed a 
200 quantitative study of KLK protein expression (KLK3-KLK15, except KLK12) by ELISA (Table 3), 
201 focusing on three immune-related tissues that according to mRNA expression data demonstrated: 1) 
202 high expression (tonsil), 2) moderate expression (spleen) and 3) low expression (lymph node) for most 
203 of the members of the KLK family (Table 2). 
204 The significantly lower levels of KLKs in lymph node and spleen suggest that KLKs may 
205 contribute to the immune response through functions in the tonsil, but not in other lymphoid tissues 
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206 (Table 3). KLKs in tonsil (Table 3) may play roles in lymphocyte activation and cell turnover through 
207 enzymatic interactions.
208 The IHC data allowed us to localize KLK expression in different immune cell types. We have 
209 shown that KLK9 and KLK10 are expressed in different immune-related cells in the tonsil (Figure 1-
210 2). KLK9 is strongly expressed in the GC of the lymphoid follicles, where activated B-cells are 
211 undergoing affinity maturation and class switch into either mature memory B cells or antibody-
212 producing plasma cells. On the other hand, KLK10 is expressed in FDCs, which collaborate with B 
213 cells to ensure efficient GC formation and the production of high-affinity antibodies (Figure 2). It is 
214 possible that these two KLKs participate in a common cascade, similar to other members such as 
215 KLK2, KLK3, KLK5 in seminal plasma: [29], and KLK5, KLK7, KLK14 in skin [30-32]. The 
216 potential co-expression and co-regulation of KLK9 and KLK10 in a cascade may be supported by the 
217 observation that they reside adjacently on the same chromosomal locus [33]. In a canine model, the 
218 two KLKs were found to be concurrently expressed in almost all tissue samples [34]. Moreover, the 
219 association between KLK9 and KLK10 in regulating the immune response has been previously implied 
220 through their role in enzymatic cascades in sweat [35], as well as by their co-upregulation upon LPS 
221 induction via CD14 and TLR4 receptors [3]. Our previous degradomic analysis also affirmed that 
222 KLK9 cleaves KLK10 [36]. It is thus possible that the two proteases may interact in the tonsil, where 
223 activated B cells (in which KLK9 is expressed) that participate in a GC reaction can interact with 
224 surface antigens on FDCs (in which KLK10 is expressed). In the future, further IHC experiments that 
225 look at the co-localization of specific cell markers with KLKs will be necessary to further evaluate our 
226 results. Moreover, further evidence is warranted to assess the putative notion that KLK9 and KLK10 
227 partake in the same proteolytic pathway, as well as how they may be involved in the process of B cell 
228 maturation in the tonsil. 
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229 The clinical utility of studying KLKs in immunity is also highly important for understanding 
230 anti-tumor responses in cancer. Some of the strongest evidence linking anti-tumor immunity and 
231 cancer are seen in ovarian cancer [37], where KLK9 and KLK10 have been implicated to aid in anti-
232 tumor [38]. Similarly, KLK15 was expressed in tonsil in our study (Figure 2E) and may hold clinical 
233 relevance in ovarian cancer [38]. KLK10 has the highest protein expression in tonsil among other KLK 
234 members (Table 3) and is located in the most potent antigen-presenting cells, the FDCs [39] in both 
235 tonsil (Figure 2C and D) and lymph node tissue (Figure 3B). Other studies have previously 
236 demonstrated the integral role of KLK10 in T-cell responses to viral antigens and the development of 
237 pro-inflammatory responses, as mediated by the adaptive immune system [40]. Recent 
238 immunopeptidome analyses demonstrated that KLK10 protein is amongst the presented immunogenic 
239 epithelial ovarian cancer antigens and is a target for antigen-specific immunotherapy [41]. 
240 Overall, our study revealed the possible implications of KLK expression and regulation in 
241 immune cells. Our data support the hypothesis that a panel of KLKs have functional significance in 
242 the immune response in tonsil. With further research into the mechanisms behind their functions in 
243 immune-related tissues and their contributions to pathology, KLKs may represent promising 
244 therapeutic targets for immune-related diseases and for cancer immunotherapy.
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404 KLK       kallikrein
405 PBS        phosphate-buffered saline
406 IHC       immunohistochemistry
407 BSA      bovine serum albumin
408 ELISA     enzyme-linked immunosorbent assay
409 ECM       extracellular matrix
410 FDCs      follicular dendritic cells
411 GC          germinal center
412 SA-ALP   alkaline phosphatase-conjugated streptavidin
413 DFP        diflunisal phosphate





418 Figure 1. KLK9, KLK10, and KLK15 are expressed in normal tonsil tissue.
419 IHC analysis of KLKs in normal tonsil tissue showed positive protein staining for KLK9 (A), KLK10 
420 (B) and KLK15 (C) (black arrows). Negative control of tonsil (D) is shown where no primary 
421 antibodies were added. Magnification: 50X. 
422
423 Figure 2. Localization of KLK9, KLK10 and KLK15 expression in different cell types in tonsil.
424 Images of immunohistochemistry staining with higher magnification (as indicated for each panel) for 
425 KLK9, KLK10, and KLK15 showed discrete patterns of cellular localization in the tonsil. KLK9 
426 showed weak staining in the squamous epithelium (blue arrow), but positive staining in the lymphoid 
427 follicles (black arrow) (A). A closer look confirms that KLK9 shows weak staining in the squamous 
428 epithelium (blue arrow), is negative in the marginal zone surrounding the lymphoid follicles (red 
429 arrow) and is strongly positive in the germinal center (GC) where activated B cells reside (black arrow) 
430 (B). KLK10 demonstrated positive staining in the follicular dendritic cells surrounding the GC (black 
431 arrow) (C-D), but not within the follicles (blue arrow) (C). KLK15 showed weak staining in the GC 
432 (blue arrow) and positive staining in the interdigitating cells (black arrow) in and subjacent to the 
433 tonsillar epithelium (E). Negative control in tonsil (F) is shown where no primary antibodies were 
434 added. 
435
436 Figure 3. KLK5 and KLK10 are expressed in different cells in normal lymph node tissue.
437 Immunohistochemistry analysis of KLKs showed positive staining for KLK5 (A) and KLK10 (B) in 
438 normal lymph node tissue. High magnification (as indicated in each panel) showed distinct cellular 
439 localization of KLK5 and KLK10 in the lymph node (A-B). KLK5 showed strongest staining in the 
17
440 peripheral cells surrounding the follicles (black arrow) (A), while KLK10 showed the strongest 
441 staining in the follicular dendritic cells (black arrow) (B). Negative control of lymph node (C) is shown 























464 Table 1. Antibodies used for immunohistochemistry (IHC)1
Kallikrein Antibody type Antibody titration for IHC Reference
KLK3 monoclonal 1/50 to 1/100 Commercial
KLK4 polyclonal 1/200 Obiezu et al 2005[42]
KLK5 monoclonal 1/50 Yousef et al 2003[43]
KLK6 monoclonal 1/100 Diamandis et al 2000[44]
KLK7 polyclonal 1/200 Walker et al 2014[45]
KLK8 polyclonal 1/200 Kishi et al 2003 [46]
KLK9 monoclonal 1/100 to 1/200 Filippou et al 2017a[24]
KLK10 monoclonal 1/100 Luo et al 2001 [47]
KLK11 polyclonal 1/250 Diamandis et al 2002[48]
KLK12 polyclonal 1/100 to1/200 Memari et al 20072[49]
KLK13 polyclonal 1/200 Kapadia et al 2003 [50]
KLK14 monoclonal 1/50 to 1/200 Borgono et al 2007 [30]
KLK15 monoclonal 1/250 Filippou et al 2018 [51]
465
466 1All monoclonal antibodies were raised in mice; all polyclonals in rabbits. All monoclonals had a 
467 concentration of 1 mg/mL.
468
469 2KLK12 antibody was only used for IHC analysis. ELISA immunoassay was not performed for KLK12 




473 Table 2. mRNA levels of KLKs in normal immune-related tissues from the Human Protein 
474 Atlas1 database 
Appendix Spleen Bone marrow
Lymph 
node Tonsil
KLK1      
KLK2      
KLK3      
KLK4      
KLK5      
KLK6      
KLK7      
KLK8      
KLK9      
KLK10      
KLK11      
KLK12      
KLK13      
KLK14      
KLK15      
     
0-0.2 0.3-0.5 0.6-0.9 1.0-10 > 10 Transcripts Per Million (TPM)


















KLK3 ND2 1.35(±0.02) ND
KLK4 0.40 (±0.04) ND ND
KLK5 1.20 (±0.007) 0.24 (±0.004) 0.11 (±0.0001)
KLK6 2.05 (±0.04) 0.13 (±0.004) ND
KLK7 3.30 (±0.06) 0.9 (±0.02) 0.085 (±0.01)
KLK8 0.39 (±0.007) 0.02 (±0.0005) ND
KLK9 4.0 (±0.04) 0.2 (±0.01) 0.02 (±0)
KLK10 9.28 (±0.07) 0.11 (±0) 0.14 (±0.0075)
KLK11 1.81 (±0.04) 0.2 (±0.01) 0.06 (±0)
KLK13 5.18 (±0.34) 0.19 (±0.02) 1.51 (±0.06)
KLK14 0.23 (±0.012) 0.05 (±0.004) ND
KLK15 0.6 (±0.007) 0.28 (±0.006) 0.2 (±0.01)
485
486 1All extracts were adjusted to 1 mg/mL of total protein. Values are means + standard deviation of 
487 triplicates 
488 2ND, not detected
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